Try
BioMarin Pharmaceutical Inc.
BMRNUnited States
79 filed reports · 509 financial concepts · 2 earnings calls · 2 media appearances
Filed reports
79 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 operating metrics, 210 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 38 | 210 | Dec 2016 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 30 | 5,124 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 5,401 | Dec 2016 to Dec 2025 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 201 | Sep 2019 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 6, 2026 | 4 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 365 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 234 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 4, 2026 | 6 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 972 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 23, 2026 | 6 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 12, 2026 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 28, 2025 | 231 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 27, 2025 | 6 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 152 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 4, 2025 | 6 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 2, 2025 | 151 | Open |
Financial data
509 concepts · 10,936 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial486 concepts · 9,755 facts · Dec 2014 to Jul 2026
- Allocated share based compensation expense58 · Dec 2014 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Comprehensive income net of tax58 · Dec 2014 to Jun 2026
- Cost of revenue (US GAAP)58 · Dec 2014 to Jun 2026
- Costs and expenses58 · Dec 2014 to Jun 2026
- Depreciation58 · Dec 2014 to Jun 2026
- Income tax expense benefit58 · Dec 2014 to Jun 2026
- Investment income interest58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Operating income loss58 · Dec 2014 to Jun 2026
- Other operating income expense net58 · Dec 2014 to Jun 2026
- Research and development expense58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Selling general and administrative expense58 · Dec 2014 to Jun 2026
- Amortization of financing costs and discounts56 · Dec 2014 to Jun 2026
- Deferred income tax expense benefit56 · Dec 2014 to Jun 2026
- Depreciation depletion and amortization56 · Dec 2014 to Jun 2026
- Foreign currency transaction gain loss unrealized56 · Dec 2014 to Jun 2026
- Income taxes paid56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in other current assets56 · Dec 2014 to Jun 2026
- Increase decrease in other noncurrent assets56 · Dec 2014 to Jun 2026
Product4 concepts · 605 facts · Dec 2014 to Jun 2026
- Revenue503 · Dec 2014 to Jun 2026
- Revenue (excluding assessed tax)92 · Mar 2019 to Dec 2022
- Inventory9 · Jun 2016 to Sep 2017
- Manufacturing costs1 · Dec 2019
Geography2 concepts · 240 facts · Dec 2014 to Mar 2026
- Revenue164 · Dec 2014 to Sep 2021
- Revenue (excluding assessed tax)76 · Dec 2020 to Mar 2026
Guidance9 concepts · 208 facts · Feb 2017 to Aug 2026
- Revenue Guidance78 · Feb 2017 to Aug 2026
- Net Income Guidance52 · Feb 2017 to Nov 2023
- EPS (Diluted) Guidance28 · Feb 2023 to Aug 2026
- Net Income Guidance (Adjusted (non-GAAP))16 · Feb 2017 to Jul 2023
- Operating Margin Guidance16 · Feb 2024 to Feb 2026
- Gross Margin Guidance8 · Feb 2023 to Nov 2023
- EPS (Diluted) Guidance (Adjusted (non-GAAP))4 · Apr 2023 to Jul 2023
- Revenue Growth Guidance4 · Jan 2019 to Feb 2020
- Effective Tax Rate Guidance2 · May 2026
Segment7 concepts · 126 facts · Dec 2022 to Jun 2026
- Research and development expense42 · Dec 2022 to Jun 2026
- Cost of revenue (US GAAP)14 · Dec 2022 to Jun 2026
- General and administrative expense (US GAAP)14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Selling and marketing expense (US GAAP)14 · Dec 2022 to Jun 2026
KPI1 concepts · 2 facts · Dec 2023 to Mar 2024
- Subscribers YoY Change2 · Dec 2023 to Mar 2024
Segments
971 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis27 members · 500 facts
- Product48 · Dec 2016 to Jun 2026
- Royalty And Other48 · Dec 2016 to Jun 2026
- ALDURAZYME39 · Dec 2016 to Jun 2026
- KUVAN39 · Dec 2016 to Jun 2026
- BRINEURA23 · Dec 2021 to Jun 2026
- NAGLAZYME23 · Dec 2021 to Jun 2026
- PALYNZIQ23 · Dec 2021 to Jun 2026
- VIMIZIM23 · Dec 2021 to Jun 2026
- VOXZOGO23 · Dec 2021 to Jun 2026
- ROCTAVIAN21 · Dec 2021 to Jun 2026
- Product four16 · Mar 2019 to Dec 2022
- Product seven16 · Mar 2019 to Dec 2022
- Product six16 · Mar 2019 to Dec 2022
- Product three16 · Mar 2019 to Dec 2022
- Product two16 · Mar 2019 to Dec 2022
- Product Four16 · Dec 2016 to Dec 2019
- Product Six16 · Dec 2016 to Dec 2019
- Product Three16 · Dec 2016 to Dec 2019
- Product Two16 · Dec 2016 to Dec 2019
- Product Seven14 · Dec 2016 to Dec 2019
- Enzyme Product11 · Dec 2021 to Dec 2023
- Aldurazyme4 · Mar 2019 to Dec 2019
- Kuvan4 · Mar 2019 to Dec 2019
- Voxzogo4 · Sep 2020 to Sep 2021
- GALAFOLD4 · Mar 2025 to Jun 2026
- POMBILITIOPFOLDA4 · Mar 2025 to Jun 2026
- Valoctocogene Roxaparvovec1 · Dec 2019
Statement geographicalsrt:StatementGeographicalAxis8 members · 172 facts
- Europe24 · Dec 2016 to Sep 2021
- Latin America24 · Dec 2016 to Sep 2021
- Rest Of World24 · Dec 2016 to Sep 2021
- US24 · Dec 2016 to Sep 2021
- Latin america22 · Dec 2020 to Mar 2026
- Rest of world18 · Dec 2021 to Mar 2026
- Us18 · Dec 2021 to Mar 2026
- Europe18 · Dec 2021 to Mar 2026
Statement business segments1 member · 126 facts
- Reportable126 · Dec 2022 to Jun 2026
Product or serviceus-gaap:ProductOrServiceAxis8 members · 105 facts
- ALDURAZYME17 · Dec 2014 to Mar 2018
- KUVAN17 · Dec 2014 to Mar 2018
- Product Three17 · Dec 2014 to Mar 2018
- Product Two17 · Dec 2014 to Mar 2018
- Product Four16 · Dec 2014 to Mar 2018
- Product Six12 · Dec 2015 to Mar 2018
- Brineura inventory5 · Jun 2016 to Sep 2017
- Vimizim pre qual inventory4 · Jun 2016 to Mar 2017
Statement geographicalus-gaap:StatementGeographicalAxis4 members · 68 facts
- Europe17 · Dec 2014 to Mar 2018
- Latin America17 · Dec 2014 to Mar 2018
- Rest Of World17 · Dec 2014 to Mar 2018
- US17 · Dec 2014 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary152 claims from 12 reports · Sep 2024 to Oct 2026
- Management discussion (MD&A) commentary44 claims from 2 reports · Dec 2024 to Dec 2025
- Risk-factor changes131 claims from 8 reports · Dec 2017 to Dec 2025
- Risk factors471 risks from 10 annual reports · 2016 to 2025
Earnings calls
2 calls · May 2026 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
- FY2026 Q1May 4, 2026
Executive media
2 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances2 · May 2020 to Nov 2020
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.